-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Brokers Offer Predictions for Legend Biotech Co.'s Q1 2023 Earnings (NASDAQ:LEGN)
Brokers Offer Predictions for Legend Biotech Co.'s Q1 2023 Earnings (NASDAQ:LEGN)
Legend Biotech Co. (NASDAQ:LEGN – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for shares of Legend Biotech in a research report issued on Tuesday, January 24th. Jefferies Financial Group analyst K. Shi expects that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for Legend Biotech's current full-year earnings is ($2.52) per share. Jefferies Financial Group also issued estimates for Legend Biotech's Q2 2023 earnings at ($0.33) EPS, Q3 2023 earnings at ($0.36) EPS, Q4 2023 earnings at ($0.32) EPS, FY2023 earnings at ($1.25) EPS, FY2024 earnings at ($0.45) EPS, FY2025 earnings at $1.07 EPS, FY2026 earnings at $2.35 EPS and FY2027 earnings at $4.10 EPS.
Get Legend Biotech alerts:Other analysts have also recently issued research reports about the stock. UBS Group initiated coverage on shares of Legend Biotech in a research report on Tuesday, December 6th. They set a "buy" rating and a $66.00 target price for the company. Barclays upped their price objective on shares of Legend Biotech from $53.00 to $65.00 and gave the company an "overweight" rating in a research report on Wednesday. Cowen initiated coverage on shares of Legend Biotech in a research report on Tuesday, November 1st. They issued an "outperform" rating for the company. Piper Sandler upped their price objective on shares of Legend Biotech from $72.00 to $78.00 and gave the company an "overweight" rating in a research report on Tuesday, December 20th. Finally, Guggenheim initiated coverage on shares of Legend Biotech in a research report on Monday, October 31st. They issued a "neutral" rating for the company. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $70.14.
Legend Biotech Stock Performance
Shares of Legend Biotech stock opened at $52.71 on Friday. The firm has a fifty day moving average of $51.28 and a two-hundred day moving average of $48.02. The stock has a market capitalization of $8.65 billion, a price-to-earnings ratio of -45.24 and a beta of -0.13. Legend Biotech has a 52 week low of $30.75 and a 52 week high of $57.72.Hedge Funds Weigh In On Legend Biotech
Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Legend Biotech by 174.8% during the 2nd quarter. FMR LLC now owns 6,663,704 shares of the company's stock worth $366,505,000 after purchasing an additional 4,239,041 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Legend Biotech by 33.9% during the 3rd quarter. Mackenzie Financial Corp now owns 172,049 shares of the company's stock worth $7,020,000 after purchasing an additional 43,561 shares in the last quarter. Aviva PLC boosted its stake in shares of Legend Biotech by 16.8% during the 2nd quarter. Aviva PLC now owns 23,600 shares of the company's stock worth $1,298,000 after buying an additional 3,400 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Legend Biotech by 4.7% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 102,516 shares of the company's stock worth $5,638,000 after buying an additional 4,613 shares during the last quarter. Finally, Samlyn Capital LLC acquired a new position in shares of Legend Biotech during the 2nd quarter worth about $24,970,000. Institutional investors own 38.88% of the company's stock.
About Legend Biotech
(Get Rating)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
Read More
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
傳奇生物(納斯達克代碼:LEGN-GET Rating)-傑富瑞金融集團的股票分析師在1月24日星期二發佈的一份研究報告中發佈了他們對傳奇生物股票2023年第一季度每股收益的估計。傑富瑞金融集團(Jefferies Financial Group)分析師K.Shih預計,該公司本季度每股收益將達到0.24美元。對新浪傳奇生物目前全年收益的普遍預期為每股2.52美元。傑富瑞金融集團還發布了對傳奇生物2023年第二季度每股收益的預測,2023年第三季度每股收益(0.36美元),2023年第四季度每股收益(0.32美元),2023財年每股收益(1.25美元),2024財年每股收益(0.45美元),2025財年每股收益1.07美元,2026財年每股收益2.35美元,以及2027財年每股收益4.10美元。
到達傳奇生物警報:其他分析師最近也發佈了關於該股的研究報告。瑞銀集團在12月6日(星期二)的一份研究報告中啟動了對傳奇生物股票的報道。他們為該公司設定了“買入”評級和66.00美元的目標價。巴克萊週三在一份研究報告中將傳奇生物的目標價從每股53.0美元上調至每股65.00美元,並給予該公司“增持”評級。考恩在11月1日星期二的一份研究報告中發起了對傳奇生物股票的報道。他們對該公司的評級為“跑贏大盤”。12月20日(星期二),派珀·桑德勒在一份研究報告中將傳奇生物的目標股價從72美元上調至78美元,並給予該公司“增持”評級。最後,古根海姆在10月31日(星期一)的一份研究報告中啟動了對傳奇生物股票的報道。他們對該公司的評級為“中性”。一名投資分析師對該股的評級為持有,九名分析師對該股的評級為買入。根據MarketBeat的數據,該股目前的平均評級為“中等買入”,平均目標價為70.14美元。
傳奇生物股票表現
上週五,新浪傳奇生物的股價開盤報52.71美元。該公司的50日移動均線切入位在51.28美元,200日移動均線切入位在48.02美元。該股市值為86.5億美元,本益比為-45.24,貝塔係數為-0.13。傳奇生物的52周低點為30.75美元,52周高點為57.72美元。對沖基金在傳奇生物上發表看法
大型投資者最近增持或減持了該公司的股份。FMR LLC在第二季度增持了174.8%的傳奇生物股份。FMR LLC在上個季度額外購買了4,239,041股後,現在擁有6,663,704股該公司股票,價值366,505,000美元。麥肯錫金融公司在第三季度增持了33.9%的傳奇生物股份。Mackenzie Financial Corp目前持有172,049股該公司股票,價值7,020,000美元,此前該公司在上個季度又購買了43,561股。英傑華在第二季度增持了16.8%的傳奇生物股份。英傑華在上個季度又購買了3,400股英傑華股票,目前持有23,600股,價值1,298,000美元。三井住友信託控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)在第二季度增持了4.7%的傳奇生物股份。三井住友信託控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)現在持有102,516股該公司股票,價值5,638,000美元,該公司在上個季度又購買了4,613股。最後,Samlyn Capital LLC在第二季度收購了價值約24,970,000美元的傳奇生物新頭寸。機構投資者持有該公司38.88%的股份。
關於傳奇生物
(獲取評級)
傳奇生物是一家臨床階段的生物製藥公司,通過其子公司,在美國和國際上從事腫瘤和其他適應症的新型細胞療法的發現和開發,中國說。其主要候選產品LCAR-B38M是一種用於治療多發性骨髓瘤(MM)的嵌合抗原受體,並與標準三聯療法治療難治性多發性骨髓瘤進行了比較。
閱讀更多內容
- 在傳奇生物上免費獲取斯托克新聞網的研究報告(樂高)
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年晶片需求回升,提振銷售觀點
- KLA公司:在動盪不安的半市場中站穩腳跟
接受傳奇生物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對傳奇生物及相關公司評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧